Navigation Links
UC Riverside bioengineer receives high honor from chemical engineers
Date:6/26/2008

cr.edu/">Bourns College of Engineering. The center, which is in the early stages of development, will intersect with industry and provide students with a wide range of research opportunities. It also will embrace an interdisciplinary approach to bioengineering and include faculty across the campus to foster biocellular engineering as a research emphasis.

"The future impact of bioengineering lies in learning how to engineer and adapt the fine-tuned intricacies of intracellular structure to direct the cell's behavior towards new and desired outcomes," Schultz said. "This is potentially a new and exciting area in bioengineering, and UCR is well positioned to excel in biocellular engineering."

Schultz started his academic career in the Department of Chemical Engineering at the University of Michigan (1964-1987), which he also chaired. He came to UCR in 2004 from the University of Pittsburgh (1987-2003), where he initiated and chaired the Department of Bioengineering, and organized the Center for Biotechnology and Bioengineering. Upon arriving at UCR, he spearheaded the development of the Department of Bioengineering, the fifth academic department in the Bourns College of Engineering, and structured its undergraduate and graduate programs.

"UCR has a rich history in engineering and biology, and a strong program in bioengineering is the inevitable next step for us," Schultz said. "The campus is gearing up for a new medical school. Given how large a role technology plays in medicine, I fully expect bioengineering to play an increasingly crucial role on campus."

Schultz's career accomplishments are extensive. His research has led to the development of techniques that could help millions of people, especially those living with diabetes. He is credited with developing a sensor that could eliminate the need for diabetics to use needles for blood glucose checks. He also is known internati
'/>"/>

Contact: Iqbal Pittalwala
iqbal@ucr.edu
951-827-6050
University of California - Riverside
Source:Eurekalert  

0

GOOD

Page: 1 2 3 4

Related biology news :

1. UC Riverside to host conference on stricter air quality standards for Southern California
2. Chemicals used as fire retardants could be harmful, UC-Riverside researchers say
3. UC-Riverside partners with Chinese university to address Chinas environmental problems
4. UC Riverside biologist receives prestigious MacArthur Fellowship
5. Brown hosts regional bioengineering conference
6. From stem cells to organs: The bioengineering challenge
7. UCSD bioengineering grad student wins leadership award
8. Cystic fibrosis patients may breathe easier, thanks to bioengineered antimicrobials
9. Bioengineers at University of Pennsylvania devise nanoscale system to measure cellular forces
10. Pitt receives $2.5 million to simulate and analyze brain, immune system activity
11. NJIT biomedical engineer receives NSF Career Development Award
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
UC Riverside bioengineer receives high honor from chemical engineers
UC Riverside bioengineer receives high honor from chemical engineers
Breaking Biology News(10 mins):White, but not pure 2White, but not pure 3Stand Up to Cancer funds high-risk/high-reward cancer research by 13 young scientists 2Stand Up to Cancer funds high-risk/high-reward cancer research by 13 young scientists 3Stand Up to Cancer funds high-risk/high-reward cancer research by 13 young scientists 4Stand Up to Cancer funds high-risk/high-reward cancer research by 13 young scientists 5Stand Up to Cancer funds high-risk/high-reward cancer research by 13 young scientists 6Miami LASIK Laser Eye Surgery Cataract Surgery Refractive Surgeon Expert Dr William Trattler Joins Select Eye Surgeons in Trusted LASIK Surgeons Di 13919 1Miami LASIK Laser Eye Surgery Cataract Surgery Refractive Surgeon Expert Dr William Trattler Joins Select Eye Surgeons in Trusted LASIK Surgeons Di 13919 2Miami LASIK Laser Eye Surgery Cataract Surgery Refractive Surgeon Expert Dr William Trattler Joins Select Eye Surgeons in Trusted LASIK Surgeons Di 13919 3Miami LASIK Laser Eye Surgery Cataract Surgery Refractive Surgeon Expert Dr William Trattler Joins Select Eye Surgeons in Trusted LASIK Surgeons Di 13919 4Miami LASIK Laser Eye Surgery Cataract Surgery Refractive Surgeon Expert Dr William Trattler Joins Select Eye Surgeons in Trusted LASIK Surgeons Di 13919 5Miami LASIK Laser Eye Surgery Cataract Surgery Refractive Surgeon Expert Dr William Trattler Joins Select Eye Surgeons in Trusted LASIK Surgeons Di 13919 6Miami LASIK Laser Eye Surgery Cataract Surgery Refractive Surgeon Expert Dr William Trattler Joins Select Eye Surgeons in Trusted LASIK Surgeons Di 13919 7Miami LASIK Laser Eye Surgery Cataract Surgery Refractive Surgeon Expert Dr William Trattler Joins Select Eye Surgeons in Trusted LASIK Surgeons Di 13919 8CyberKnife Treatment for Medically Inoperable Lung Cancer 56512 1CyberKnife Treatment for Medically Inoperable Lung Cancer 56512 2Raleigh Comprehensive and Cosmetic Dentistry Announces Addition of New Practice to Raleigh Dentist Family 56508 1Raleigh Comprehensive and Cosmetic Dentistry Announces Addition of New Practice to Raleigh Dentist Family 56508 2
Breaking Biology Technology:Breakthrough TriPollar Technology- the Most Advanced Anti-Aging Solution- to Launch into High Growth Brazilian Market for Aesthetic Procedures 2Breakthrough TriPollar Technology- the Most Advanced Anti-Aging Solution- to Launch into High Growth Brazilian Market for Aesthetic Procedures 3RE-COVER Study Evaluating Dabigatran Etexilate Met Primary Outcome for the Six-Month Treatment of Patients with Acute Venous Thromboembolism (VTE) 2RE-COVER Study Evaluating Dabigatran Etexilate Met Primary Outcome for the Six-Month Treatment of Patients with Acute Venous Thromboembolism (VTE) 3RE-COVER Study Evaluating Dabigatran Etexilate Met Primary Outcome for the Six-Month Treatment of Patients with Acute Venous Thromboembolism (VTE) 4RE-COVER Study Evaluating Dabigatran Etexilate Met Primary Outcome for the Six-Month Treatment of Patients with Acute Venous Thromboembolism (VTE) 5RE-COVER Study Evaluating Dabigatran Etexilate Met Primary Outcome for the Six-Month Treatment of Patients with Acute Venous Thromboembolism (VTE) 6Alberta companies delivering new products to the health & medical marketplace 2JourneyLite of Houston Now Offering Sleeve Gastrectomy 2
Other Biology Technology:Simcere Pharmaceutical Group Reports Unaudited Fourth Quarter and Fiscal Year 2008 Results 2Simcere Pharmaceutical Group Reports Unaudited Fourth Quarter and Fiscal Year 2008 Results 3Simcere Pharmaceutical Group Reports Unaudited Fourth Quarter and Fiscal Year 2008 Results 4Simcere Pharmaceutical Group Reports Unaudited Fourth Quarter and Fiscal Year 2008 Results 5Simcere Pharmaceutical Group Reports Unaudited Fourth Quarter and Fiscal Year 2008 Results 6Simcere Pharmaceutical Group Reports Unaudited Fourth Quarter and Fiscal Year 2008 Results 7Simcere Pharmaceutical Group Reports Unaudited Fourth Quarter and Fiscal Year 2008 Results 8Simcere Pharmaceutical Group Reports Unaudited Fourth Quarter and Fiscal Year 2008 Results 9Simcere Pharmaceutical Group Reports Unaudited Fourth Quarter and Fiscal Year 2008 Results 10Simcere Pharmaceutical Group Reports Unaudited Fourth Quarter and Fiscal Year 2008 Results 11Simcere Pharmaceutical Group Reports Unaudited Fourth Quarter and Fiscal Year 2008 Results 12Simcere Pharmaceutical Group Reports Unaudited Fourth Quarter and Fiscal Year 2008 Results 13Kibow Biotech Strongly Supports World Kidney Day for Maintenance of Healthy Kidney Function 2Kibow Biotech Strongly Supports World Kidney Day for Maintenance of Healthy Kidney Function 3Micromet, Inc. To Regain Rights to Blinatumomab in North America; Reports Financial Results for the Fourth Quarter and Full Year ended December 31, 2008 2Micromet, Inc. To Regain Rights to Blinatumomab in North America; Reports Financial Results for the Fourth Quarter and Full Year ended December 31, 2008 3Micromet, Inc. To Regain Rights to Blinatumomab in North America; Reports Financial Results for the Fourth Quarter and Full Year ended December 31, 2008 4Micromet, Inc. To Regain Rights to Blinatumomab in North America; Reports Financial Results for the Fourth Quarter and Full Year ended December 31, 2008 5Micromet, Inc. To Regain Rights to Blinatumomab in North America; Reports Financial Results for the Fourth Quarter and Full Year ended December 31, 2008 6Micromet, Inc. To Regain Rights to Blinatumomab in North America; Reports Financial Results for the Fourth Quarter and Full Year ended December 31, 2008 7Micromet, Inc. To Regain Rights to Blinatumomab in North America; Reports Financial Results for the Fourth Quarter and Full Year ended December 31, 2008 8Micromet, Inc. To Regain Rights to Blinatumomab in North America; Reports Financial Results for the Fourth Quarter and Full Year ended December 31, 2008 9Micromet, Inc. To Regain Rights to Blinatumomab in North America; Reports Financial Results for the Fourth Quarter and Full Year ended December 31, 2008 10Micromet, Inc. To Regain Rights to Blinatumomab in North America; Reports Financial Results for the Fourth Quarter and Full Year ended December 31, 2008 11Micromet, Inc. To Regain Rights to Blinatumomab in North America; Reports Financial Results for the Fourth Quarter and Full Year ended December 31, 2008 12